The new meta‐oxoborates γ‐RE(BO2)3 (RE = La ‐ Nd) (≡ REB3O6) were obtained as colourless (La, Ce), light green (Pr) and pale violet (Nd) crystalline powders by the reaction of CeO2, Pr6O11, or RE2O3 (RE = La, Nd) and B2O3 in a Walker‐type multianvil apparatus under high‐pressure/high‐temperature conditions of 7.5 GPa and 1000 °C. The single crystal X‐ray structure determination of γ‐Ce(BO2)3 revealed: Pca21, a = 1845.7(2), b = 446.8(2), c = 429.5(2) pm, Z = 4, R1 = 0.0265, wR2 = 0.0451 (all data). For the isotypic compounds γ‐RE(BO2)3 (RE = La, Pr, Nd) the corresponding lattice parameters were obtained from powder data. Structurally, the compounds represent a new type of rare‐earth meta‐oxoborate RE(BO2)3 in addition to the well characterized monoclinic (RE = La ‐ Nd, Sm ‐ Lu; C2/c) and orthorhombic (RE = Tb ‐ Lu; Pnma) phases. Considering the increasing number of polymorphs, we introduced greek letter prefixes to the rare‐earth meta‐oxoborates, labeling the former known monoclinic phases as α‐RE(BO2)3 (space group: C2/c), the orthorhombic phases as β‐RE(BO2)3 (space group: Pnma), and the here presented orthorhombic phases as γ‐RE(BO2)3. Furthermore, we report about temperature‐resolved in‐situ powder‐diffraction measurements, and IR‐spectroscopic investigations into γ‐Ce(BO2)3.
No takes yet. Share an insight, caveat, or question.
Emme et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: